Composition for reducing or alleviating post-treatment symptoms after non-surgical cosmetic therapy

Abstract

To provide a composition for reducing or alleviating post-treatment symptoms after non-surgical cosmetic therapy involving invasion to the skin.SOLUTION: A composition for reducing or alleviating post-treatment symptoms after non-surgical cosmetic therapy involving invasion to the skin, characterized in that the composition contains nicotinamide mononucleotide as an active ingredient. The composition is preferably a topical preparation for the skin, the non-surgical cosmetic therapy is preferably microneedle treatment, laser treatment, or light treatment, and the post-treatment symptom is preferably redness of the skin.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to compositions for reducing or alleviating post-treatment symptoms following non-surgical cosmetic treatments involving invasive skin procedures. [Background technology]

[0002] In recent years, growing awareness of beauty has led to an increasing demand for cosmetic treatments for the skin, particularly the face. These cosmetic treatments can be classified into surgical procedures (e.g., facelifts) and non-surgical procedures (e.g., microneedle treatments, laser treatments) (Non-Patent Document 1). Non-surgical cosmetic treatments have the advantage of being less invasive than surgical treatments, but it is still difficult to completely avoid post-treatment symptoms such as redness, swelling, and bloating. The period until these post-treatment symptoms subside and normal life returns is called downtime, and the challenge is how to reduce or alleviate post-treatment symptoms and shorten downtime.

[0003] With regard to how to alleviate or mitigate post-procedure symptoms and how to shorten downtime, emphasis has been placed on selecting methods or developing new methods (Non-Patent Document 2). However, at present, there is little knowledge about how to alleviate or mitigate post-procedure symptoms and shorten downtime if they occur.

[0004] Nicotinamide mononucleotide (hereinafter sometimes abbreviated as "NMN") is a component that is expected to help prevent age-related diseases (Non-Patent Document 3), but its relationship with post-treatment symptoms following non-surgical cosmetic therapy was completely unknown. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Juntendo Medical Journal, 2013, Vol. 59, No. 4, pp. 321-326 [Non-patent document 2] Shinshu Medical Journal, 2022, Vol.70, No.2, pp.69-80 [Non-patent document 3] Cell Metab.,2018,vol.27,pp.513-528 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention aims to provide a composition for reducing or alleviating post-treatment symptoms of non-surgical cosmetic treatments involving skin invasion. [Means for solving the problem]

[0007] As a result of research conducted by the present inventors to solve the above problems, they found that administration of nicotinamide mononucleotide can reduce or alleviate the above post-operative symptoms, and thus completed the present invention. Specifically, the present invention is as follows.

[0008] [1] A composition for reducing or alleviating symptoms after a non-surgical cosmetic treatment involving skin invasion, comprising: A composition characterized by containing nicotinamide mononucleotide as an active ingredient. [2] The composition according to [1], which is a topical skin preparation. [3] The composition according to [1], wherein the non-surgical cosmetic treatment is microneedle treatment, laser treatment, or phototherapy. [4] The composition according to [1], wherein the post-treatment symptom is redness of the skin. [Effects of the Invention]

[0009] The composition of the present invention can reduce or alleviate symptoms after non-surgical cosmetic treatments that involve invasive treatment of the skin. [Brief explanation of the drawings]

[0010] [Figure 1] This is a graph showing the results of monitoring the symptoms of monitor 02 after Dermapen treatment using a skin diagnostic device. [Figure 2] This is a graph showing the results of monitoring the symptoms of monitor 03 after Dermapen treatment using a skin diagnostic device. [Figure 3] This is a graph showing the results of monitoring the symptoms of monitor 04 after Dermapen treatment using a skin diagnostic device. DETAILED DESCRIPTION OF THE INVENTION

[0011] Hereinafter, an embodiment of the present invention will be described. A composition according to an embodiment of the present invention is a composition for reducing or alleviating symptoms after a non-surgical cosmetic treatment involving invasion of the skin, and is characterized by containing nicotinamide mononucleotide as an active ingredient.

[0012] (Non-surgical beauty therapy) The cosmetic treatment method targeted by this embodiment is a non-surgical cosmetic treatment method involving invasion of the skin. In this specification, "non-surgical cosmetic therapy" refers to a cosmetic therapy that does not involve incision of the affected area, and "invasive to the skin" refers to a therapy that involves destruction of skin tissue. Therefore, the "non-surgical cosmetic therapy that involves invasion of the skin" that is the subject of this embodiment includes cosmetic therapy that involves (micro) destruction of skin tissue by needle puncture, laser irradiation, etc., but does not include cosmetic therapy that involves incision of the affected area, such as face lift surgery, or cosmetic therapy that does not involve invasion of the skin, such as administration of oral medication or application of topical agents such as ointments.

[0013] The beauty therapy targeted by this embodiment may be a planar treatment applied to the skin. Here, "planar treatment" includes: a case where a laser or light beam is applied to the skin in a planar manner; and a case where a point treatment is applied to the skin by needle puncture or irradiation of a laser or light beam, etc., and the treatment is applied to multiple points (points), resulting in a planar treatment. When invasive non-surgical cosmetic therapy is performed on a surface area, the post-treatment symptoms described below are likely to occur. However, according to this embodiment, even when non-surgical cosmetic therapy is performed on a surface area, the post-treatment symptoms can be reduced or alleviated.

[0014] Such non-surgical cosmetic treatments include microneedle treatments, laser treatments, and phototherapy.

[0015] Microneedle therapy is a technique that uses ultra-fine needles to puncture the skin, activating fibroblasts and epidermal cells and inducing the remodeling of skin tissue, improving skin elasticity and quality. Furthermore, cosmetic ingredients can be injected through the ultra-fine needles, or electromagnetic waves such as high frequency waves can be directly irradiated into the skin through the ultra-fine needles. Examples of microneedle therapy include dermapen, hydrophobic injections, and radio frequency (RF) fractional needling.

[0016] Laser therapy is a method of selectively destroying targeted substances, cells, and tissues by irradiating the skin with a laser, eliminating blemishes, or activating fibroblasts and epidermal cells to induce the reconstruction of skin tissue and improve skin elasticity and texture. This method is based on the theory of selective photothermolysis (SP), and various lasers are used depending on the type of target. The skin may be irradiated by planar irradiation or by point irradiation divided into many fine beams (so-called fractional laser). The wavelength of the laser, irradiation time, etc. may be appropriately selected depending on the purpose.

[0017] Phototherapy is a method of irradiating the skin with light of various wavelengths (i.e., not lasers), and is based on SP theory, just like laser therapy. Examples of phototherapy include broadband pulsed light (Intense Pulsed Light, IPL).

[0018] (Symptoms after treatment) The symptoms that the composition according to this embodiment relieves or alleviates are post-treatment symptoms of the above-mentioned non-surgical cosmetic treatment (hereinafter, sometimes simply referred to as "post-treatment symptoms"). Such post-treatment symptoms include redness, swelling, puffiness, and internal bleeding. The non-surgical cosmetic treatments that are the subject of this embodiment involve invasion (i.e., a step that partially destroys skin tissue), and it is difficult to completely avoid the above-mentioned post-treatment symptoms, but by applying the composition according to this embodiment, it is possible to reduce or alleviate such post-treatment symptoms.

[0019] The composition according to this embodiment is particularly effective in reducing or alleviating redness. Furthermore, the composition according to the present embodiment can reduce or alleviate the above-mentioned post-treatment symptoms, thereby shortening downtime and enabling patients to return to normal life more quickly, thereby reducing the burden on patients caused by the above-mentioned beauty treatment.

[0020] (nicotinamide mononucleotide) Nicotinamide mononucleotide (NMN) used in this embodiment is a compound represented by the following structural formula.

[0021] [ka]

[0022] NMN exists as α- and β-optical isomers, but in this embodiment, the β-form is used. NMN can be obtained by chemical synthesis or enzymatic reaction, or it can be produced by organisms such as yeast and purified. Commercially available NMN can also be used.

[0023] The administration method of NMN includes transdermal administration, oral administration, etc., but transdermal administration is preferable from the viewpoint of ease of reaching the treatment site. In other words, the composition according to this embodiment is preferably a skin external preparation. NMN may be added directly to compositions such as topical skin preparations, or may be formulated and then added.

[0024] The types of topical skin preparations that can contain NMN are not particularly limited, and examples include ointments, creams, emulsions, skin lotions, lotions, gels, cosmetic oils, packs, foundations, shampoos, and rinses.

[0025] When NMN is incorporated into a topical skin preparation, the amount can be adjusted appropriately depending on the type of topical skin preparation, but can be, for example, 0.000001% by mass or more, 0.0001% by mass or more, 0.001% by mass or more, or 0.1% by mass or more, calculated as the mass of NMN. The upper limit of the amount is not particularly limited, and can be adjusted appropriately to, for example, 50% by mass or less, 10% by mass or less, 2% by mass or less, etc.

[0026] The topical skin preparation of this embodiment can be used in combination with main ingredients, auxiliary agents, or other ingredients typically used in the manufacture of topical skin preparations, such as moisturizers, cell activators, astringents, germicides / antibacterial agents, whitening agents, UV absorbers, anti-inflammatory / antiallergic agents, antioxidants / active oxygen scavengers, oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, fragrances, etc., as long as the use of such combinations does not interfere with the effect of NMN, i.e., the alleviation / relief of post-treatment symptoms. Such combinations can result in a more general-purpose product, and the synergistic effect with the other active ingredients used in combination can sometimes bring about superior effects beyond those normally expected.

[0027] The above-described embodiments have been described to facilitate understanding of the present invention, and are not intended to limit the present invention. Therefore, each element disclosed in the above embodiments is intended to include all design modifications and equivalents that fall within the technical scope of the present invention. [Example]

[0028] The present invention will be explained in more detail below by showing test examples, etc., but the present invention is not limited to the following test examples, etc.

[0029] [Test Example 1] Effect of Dermapen on post-treatment symptoms - 1 (1) Manufacturing of the test product A test product (NMN-containing product, lotion B) with the following composition was manufactured. Nicotinamide mononucleotide (NMN) 0.20 parts by mass Glycerin 3.60 parts by mass 1,3-butylene glycol (BG) 1.00 parts by mass Phenoxyethanol 0.80 parts by mass 1,3-Hexanediol 0.40 parts by mass Sodium hyaluronate 0.025 parts by mass Purified water, balance (total amount is 100 parts by mass)

[0030] A control product (lotion A) was also produced that had the same composition but did not contain NMN.

[0031] (2) Subjects This study targeted women aged 20 to 65 who had no skin diseases in the treatment area, and one subject (Monitor 01) was selected. The content of the study was fully explained to the subjects, and consent to participate in the study was obtained from all subjects before the study was conducted.

[0032] (3) Test method After a dermapen treatment on the entire face at a beauty clinic, the subjects were asked to apply a control product (lotion A) and a test product (lotion B) to half of their face each day, and the progress of symptoms after treatment was observed. The subjects were not informed which lotion A or B contained NMN.

[0033] The follow-up observation was carried out by the subjects themselves assessing the redness and taking photographs. The subjects' evaluation was based on the following criteria: =Redness rating= 5: (Overall) Very red 4: (Overall) slightly red 3: (Overall) Slightly red 2: (Some areas) Redness remains 1: No redness The results of the evaluation by the subjects are shown in Table 1, and the evaluation based on the photographs taken is shown in Table 2.

[0034] [Table 1]

[0035] [Table 2]

[0036] As shown in Tables 1 and 2, the areas where the NMN-containing product (lotion B) was applied showed reduced redness after Dermapen treatment, and the time it took for the redness to disappear was also shortened.

[0037] [Test Example 2] Effect of Dermapen on post-treatment symptoms - 2 (1) Manufacturing of the test product A test product (NMN-containing product, lotion C) was produced in the same manner as in Test Example 1, except that the amount of NMN was changed to 1 part by mass. The control product in this test had the same composition as lotion A used in Test Example 1.

[0038] (2) Subjects This study targeted three women (Monitors 02-04) aged 20-65 who did not have any skin diseases in the treatment area. The subjects were given a full explanation of the study and all consent to participate was obtained before the study was conducted.

[0039] (3) Test method After a dermapen treatment on the entire face at a beauty clinic, the subjects were asked to apply a control product (lotion A) and a test product (lotion C) to half of their face each day, and the progress of symptoms after treatment was observed. The subjects were not informed which lotion A or C contained NMN.

[0040] The follow-up observation was carried out by the subjects themselves assessing redness and using a skin diagnostic and analysis device (Robo Skin Analyzer CS50, manufactured by Shibuya Kogyo Co., Ltd.). The subjects' evaluation was based on the following criteria: =Redness rating= 5: (Overall) Very red 4: (Overall) slightly red 3: (Overall) Slightly red 2: (Some areas) Redness remains 1: No redness

[0041] For evaluation using the skin diagnostic device, the treated area (i.e., the face) was photographed, and the number and area of ​​redness (Level 1) was tallied and compared between the left and right sides (i.e., the areas where the test product was applied and the areas where the control product was applied). The results of the evaluation by the subjects are shown in Table 3, and the evaluation by the skin diagnostic device is shown in Figures 1 to 3, respectively.

[0042] [Table 3]

[0043] As shown in Table 3, Figures 1 and 2, for monitors 02 and 03, both the subjects' own evaluation and the evaluation using the skin diagnostic device showed that the areas where the NMN-containing product (lotion C) was applied showed reduced redness after Dermapen treatment, and the time it took for the redness to disappear was also shortened. On the other hand, in Monitor 04, no difference was found between the test product and the control product in the subject's own evaluation (Table 3), but evaluation using the skin diagnosis machine showed that the redness symptoms after Dermapen treatment were reduced in the areas where the NMN-containing product (lotion C) was applied (Figure 3).

[0044] [Test Example 3] Effects of pico fractional laser on post-treatment symptoms (1) Manufacturing of the test product The test products were the same as those in Test Example 2, and a test product (product containing 1% NMN, lotion C) and a control product were used.

[0045] (2) Subjects This study targeted two women (Monitors 05 and 06) aged 20 to 65 who had no skin diseases in the treatment area. The subjects were given a full explanation of the study, and consent to participate was obtained from all subjects before the study was conducted.

[0046] (3) Test method After pico fractional laser treatment on the entire face at a beauty clinic, subjects applied a control product (lotion A) and a test product (lotion C) to half of their face each day, and the progress of symptoms after treatment was observed. The laser was used at high power to make it easier to evaluate post-treatment symptoms. Furthermore, subjects were given lotions A and C without knowing which one contained NMN.

[0047] The follow-up observation was carried out by the subjects themselves assessing the redness, according to the following criteria: =Redness rating= 5: (Overall) Very red 4: (Overall) slightly red 3: (Overall) Slightly red 2: (Some areas) Redness remains 1: No redness The results are shown in Table 4.

[0048] [Table 4]

[0049] As shown in Table 4, the areas where the NMN-containing product (lotion C) was applied showed reduced redness after pico fractional laser treatment, and the time it took for the redness to disappear was also shortened.

Claims

1. A composition for reducing or alleviating symptoms after a non-surgical cosmetic treatment involving skin invasion, comprising: A composition characterized by containing nicotinamide mononucleotide as an active ingredient.

2. The composition according to claim 1, which is an external skin preparation.

3. The composition of claim 1 , wherein the non-surgical cosmetic treatment is microneedling treatment, laser treatment, or light treatment.

4. The composition of claim 1 , wherein the post-treatment symptom is redness of the skin.

Images